» Articles » PMID: 27528673

Scavenging Nucleic Acid Debris to Combat Autoimmunity and Infectious Disease

Overview
Specialty Science
Date 2016 Aug 17
PMID 27528673
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Nucleic acid-containing debris released from dead and dying cells can be recognized as damage-associated molecular patterns (DAMPs) or pattern-associated molecular patterns (PAMPs) by the innate immune system. Inappropriate activation of the innate immune response can engender pathological inflammation and autoimmune disease. To combat such diseases, major efforts have been made to therapeutically target the pattern recognition receptors (PRRs) such as the Toll-like receptors (TLRs) that recognize such DAMPs and PAMPs, or the downstream effector molecules they engender, to limit inflammation. Unfortunately, such strategies can limit the ability of the immune system to combat infection. Previously, we demonstrated that nucleic acid-binding polymers can act as molecular scavengers and limit the ability of artificial nucleic acid ligands to activate PRRs. Herein, we demonstrate that nucleic acid scavengers (NASs) can limit pathological inflammation and nucleic acid-associated autoimmunity in lupus-prone mice. Moreover, we observe that such NASs do not limit an animal's ability to combat viral infection, but rather their administration improves survival when animals are challenged with lethal doses of influenza. These results indicate that molecules that scavenge extracellular nucleic acid debris represent potentially safer agents to control pathological inflammation associated with a wide range of autoimmune and infectious diseases.

Citing Articles

Multifunctional nanoparticles confers both multiple inflammatory mediators scavenging and macrophage polarization for sepsis therapy.

Xi W, Wu W, Zhou L, Zhang Q, Yang S, Huang L Mater Today Bio. 2025; 30():101421.

PMID: 39811612 PMC: 11732566. DOI: 10.1016/j.mtbio.2024.101421.


Treating acute lung injury through scavenging of cell-free DNA by cationic nanoparticles.

Huang Z, Wei C, Xie H, Xiao X, Wang T, Zhang Y Mater Today Bio. 2024; 29:101360.

PMID: 39687793 PMC: 11648789. DOI: 10.1016/j.mtbio.2024.101360.


Synthetic polypeptides inhibit nucleic acid-induced inflammation in autoimmune diseases by disrupting multivalent TLR9 binding to LL37-DNA bundles.

Liu X, Chen S, Huang J, Du Y, Luo Z, Zhang Y Nat Nanotechnol. 2024; 19(11):1745-1756.

PMID: 39160338 DOI: 10.1038/s41565-024-01759-2.


Intranasal PAMAM-G3 scavenges cell-free DNA attenuating the allergic airway inflammation.

Chen X, Chen C, Tu Z, Guo Z, Lu T, Li J Cell Death Discov. 2024; 10(1):213.

PMID: 38698016 PMC: 11065999. DOI: 10.1038/s41420-024-01980-x.


Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-132.

Burge D, Werth V, Boackle S, Posada J Lupus Sci Med. 2024; 11(1).

PMID: 38325898 PMC: 10860108. DOI: 10.1136/lupus-2023-001113.


References
1.
Jiang W, Zhu F, Bhagat L, Yu D, Tang J, Kandimalla E . A Toll-like receptor 7, 8, and 9 antagonist inhibits Th1 and Th17 responses and inflammasome activation in a model of IL-23-induced psoriasis. J Invest Dermatol. 2013; 133(7):1777-84. DOI: 10.1038/jid.2013.57. View

2.
Nickerson K, Christensen S, Shupe J, Kashgarian M, Kim D, Elkon K . TLR9 regulates TLR7- and MyD88-dependent autoantibody production and disease in a murine model of lupus. J Immunol. 2010; 184(4):1840-8. PMC: 4098568. DOI: 10.4049/jimmunol.0902592. View

3.
Salloum R, Niewold T . Interferon regulatory factors in human lupus pathogenesis. Transl Res. 2011; 157(6):326-31. PMC: 3096827. DOI: 10.1016/j.trsl.2011.01.006. View

4.
Murphy G, Lisnevskaia L, Isenberg D . Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment. Lancet. 2013; 382(9894):809-18. DOI: 10.1016/S0140-6736(13)60889-2. View

5.
Svenson S, Tomalia D . Dendrimers in biomedical applications--reflections on the field. Adv Drug Deliv Rev. 2005; 57(15):2106-29. DOI: 10.1016/j.addr.2005.09.018. View